Compared with the normal, the expression of PERK mRNA was upregulated in brain and CNS cancer, breast cancer, head and neck cancer, and other cancers (all p < 0.05) and downregulated in lymphoma and sarcoma (all p < 0.05) in the Oncomine database. Here, EIF2AK3 is linked to breast cancer.